48.74
+8.21%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Edgewise Therapeutics
From its filings with the US Securities and Exchange Commission
Edgewise Therapeutics is based in Boulder, Colorado and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker EWTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $167.8m. At that date it held total assets of $552.6m and shareholders' equity of $522.3m.
Our mission is to discover new medicines that improve the lives of people facing serious muscle disease.
At Edgewise, we appreciate the life-limiting impact of serious muscle diseases. Our science-driven culture places patients first as we start with their unmet needs and then work towards developing therapies to help address the significant challenges of serious muscle diseases. Guided by our holistic drug discovery approach to targeting the muscle as an organ, we have combined our foundational expertise in muscle biology and small molecule engineering to build our proprietary, muscle focused drug discovery platform. Our platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. We have developed and characterized a library of novel sarcomere modulators exhibiting a broad range of pharmacological and pharmacokinetic (PK) properties regulating disease-related muscle biology. Based on the results of our drug discovery platform, we are advancing multiple clinical-stage programs in muscular dystrophies and severe cardiac diseases, as well as a number of preclinical programs.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 26 Mar 2021
- Employees
- 146
- Website
- edgewisetx.com ↗
- Head office
- 1715 38TH ST, BOULDER, CO, 80301
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Peter ThompsonIndependent Chairman of the Board, Co-Founder$326,888
- Dr. Kevin KochPresident, Chief Executive Officer, Director, since 2017$7.6m
- Dr. Alan RussellChief Scientific Officer, Director, Co-Founder, since 2017$2.5m
- Mr. R. Michael CarruthersChief Financial Officer$550,351
- Dr. Behrad DerakhshanChief Operating Officer$2.9m
- Mr. John MooreGeneral Counsel
- Mr. Robert BlausteinChief Development Officer
- Dr. Joanne DonovanChief Medical Officer$2.9m
- Ms. Laura BregeIndependent Director$307,317
- Dr. Badreddin EdrisIndependent Director, Co-Founder$295,965
- Dr. Jonathan FoxIndependent Director$291,317
- Ms. Arlene MorrisIndependent Director$282,164
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 56
- Environment
- 56
- Social
- 87
- Governance
- 25
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Boulder, Colorado with 146 employees.
- Focus on discovery, development, and commercialization of treatments for rare neuromuscular and cardiac disorders.
- Lead candidate EDG-5506 is in multiple clinical trials for muscular dystrophies and McArdles disease.
Weaknesses
- Company has 146 employees, which may be limited for a clinical-stage biopharmaceutical company.
- IPO occurred in 2021, indicating relatively recent market entry.
- Company is focused on rare diseases, which may limit market size.
Opportunities
- Advancing EDG-5506 in clinical trials for multiple muscular dystrophies could lead to regulatory approvals.
- EDG-7500 for hypertrophic cardiomyopathy is in preclinical development, offering potential future product pipeline.
- Muscle-focused drug discovery platform could be leveraged for additional therapeutic areas.
Threats
- Clinical trials for EDG-5506 may fail, delaying or halting development.
- Rare disease focus may face challenges in patient recruitment for clinical trials.
- Competition in the pharmaceutical sector for rare disease treatments could increase.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.